CapsoVision (CV) Registration Filing summary

Company overview and business model

• Commercial-stage medical technology company focused on GI tract diagnostics using advanced imaging and AI technologies in capsule endoscopy solutions.

• Main products: CapsoCam Plus (small bowel) and CapsoCam Colon (colon), both offering 360° panoramic imaging and cloud-based data management.

• CapsoCam Plus is FDA-cleared for small bowel use; CapsoCam Colon is in pivotal studies targeting FDA clearance in 2026.

• Revenue is generated from direct sales in the U.S. and through distributors internationally, with a growing direct sales presence in key markets like Germany.

• Plans to expand indications to esophageal and pancreatic conditions, leveraging AI and cloud data for future product development.

Financial performance and metrics

• Revenue grew from $9.8M in 2023 to $11.8M in 2024 (21% YoY growth); Q1 2025 revenue was $2.8M, up 12% YoY.

• Gross margin was 54% in 2024, with gross profit of $6.4M.

• Net losses: $11.3M in 2023, $19.9M in 2024, and $5.4M in Q1 2025; accumulated deficit of $135.7M as of March 31, 2025.

• Cash balance of $4.4M as of March 31, 2025; pro forma as adjusted cash post-IPO estimated at $27.2M.

• Substantial doubt about ability to continue as a going concern; additional capital likely needed beyond IPO proceeds.

Use of proceeds and capital allocation

• Estimated net proceeds of $22.8M (at $5.25/share midpoint) to be used for: $8M R&D (AI, CapsoCam Colon, clinical studies), $1M loan repayment, and the remainder for general corporate purposes.

• Management has broad discretion over use of funds; proceeds may be invested in short-term, investment-grade securities pending use.